<DOC>
	<DOCNO>NCT00922623</DOCNO>
	<brief_summary>This study ass safe effective investigational product , Belotero® people skin type facial wrinkle , nasolabial fold . Nasolabial fold wrinkle face go outside nostril edge mouth .</brief_summary>
	<brief_title>Safety Effectiveness Belotero® Subjects With Fitzpatrick Phototypes IV Through VI</brief_title>
	<detailed_description>The Fitzpatrick Skin Phototype Scale go number 1 ( I ) , light skin tone , number 6 ( VI ) dark skin tone . This study determine safety effectiveness Belotero® people skin phototypes 1 ( I ) thru 6 ( VI ) .</detailed_description>
	<criteria>1 . Had review sign statement Informed Consent HIPAA authorization . In addition , subject ask provide separate release use photographs publication . Subjects right refuse photo release without jeopardize eligibility participate study . 2 . Was 18 75 year age , race sex . 3 . If female , postmenopausal least one year ; undergone hysterectomy ; tubal ligation ; childbearing potential , negative urine pregnancy test result agree use approved method birth control throughout study ( ie , oral/systemic contraceptive , intrauterine device [ IUD ] , spermicide combination barrier method contraception ) , abstinent , monogamous relationship partner vasectomy . 4 . Had bilateral nasolabial fold severity 2 3 wrinkle severity rating scale ( SRS ) assess Evaluator Investigator . 5 . Subjects rat IV , V , VI Fitzpatrick Skin Phototype Scale . 6 . Had adequate understanding language ( spoken write English Spanish ) willing comply study requirement . 1 . A personal history allergic/anaphylactic reaction include hypersensitivity local anesthetic ( eg , lidocaine , etc ) , hyaluronic acid ( HA ) preparation , and/or grampositive bacterial protein . 2 . A known history keloid bleed disorder . 3 . Leukoderma ( vitiligo ) family history leukoderma pigmentary disorder . 4 . An active inflammatory process nasolabial fold area ( skin eruption cyst , pimple , rash , cancerous/precancerous lesion , psoriasis , neurodermatitis , active skin disease ) severe scar might interfere study assessment . 5 . If female , pregnant , plan become pregnant study , breast feeding . 6 . Planned undergo major facial surgery course study ( eg , rhinoplasty [ without implant ] , facelift , congenital defect repair , etc ) . 7 . Clinically important disease , judge investigator , within 3 month study ( eg , significant laboratory test abnormality , myocardial infarct , stroke , cancer , connective tissue disease [ scleroderma , systemic lupus erythematous ] , systemic infection , uncontrolled diabetes , etc . ) , include medical condition might require use immunosuppressive medication trial ( eg , severe , uncontrolled asthma , rheumatoid arthritis , autoimmune disease , etc ) . 8 . Severe physical , neurological mental disease . 9 . Excessive facial hair might interfere evaluation wrinkle assessment . 10 . Any systemic dermatologic disorder , , opinion investigator , would interfere study result increase risk AEs . 11 . Had use exclusionary medications/treatments . 12 . Participation clinical investigation within 30 day prior first plan device administration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Nasolabial fold</keyword>
</DOC>